Welcome to LookChem.com Sign In|Join Free

CAS

  • or

127984-74-1

Post Buying Request

127984-74-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

127984-74-1 Usage

Description

Lanreotide acetate, an octapeptide somatostatin analog, reached its first worldwide market in France for acromegaly when surgery or radiotherapy have failed to restore normal growth hormone secretion. Lanreotide is a selective inhibitor of growth hormone and reduces the secretion of growth hormone, thyrotropin, motilin and pancreatic polypeptide in humans. Lanreotide has antiproliferative properties and is reportedly in clinical trials for the prevention of restenosis following coronary artery angioplasty, for diabetic retinopathy, and as a therapy for psoriasis. Its potential for neuroendocrine tumors and hormone-responsive prostate cancer has also been demonstrated.

Originator

Beaufour-Ipsen (France)

Uses

Different sources of media describe the Uses of 127984-74-1 differently. You can refer to the following data:
1. Lanreotide acetate has been used as an inhibitor to test the plasticity of hydrogen sulfide modulation by growth hormone/thyroid hormone signaling in wild-type mice.
2. Lanreotide Acetate is a drug used in the control and prevention of glycemia and hypoglycemic brain damage without surgery in patients diagnosed with congenital hyperinsulinism. It improves outcomes in patients suffering from acromegalyresulting from invasive pituitary macroadenoma.

Brand name

Somatuline LP

Biochem/physiol Actions

Lanreotide acetate is a somatostatin analog, a selective agonist for the SRIF-1 sst2 subtype of somatostatin receptor with a binding affinity of 0.8 nM for sst2 compared to 5.2 nM for sst5, 100 nM for sst3 and more than 1000 nM for the SRIF-2 subtypes, sst1 and sst4 receptors. It is used clinically in the management of acromegaly and symptoms caused by neuroendocrine tumors, and in recent studies can also inhibit tumor growth and has shown activity against non-endocrine tumors.

Check Digit Verification of cas no

The CAS Registry Mumber 127984-74-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,7,9,8 and 4 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 127984-74:
(8*1)+(7*2)+(6*7)+(5*9)+(4*8)+(3*4)+(2*7)+(1*4)=171
171 % 10 = 1
So 127984-74-1 is a valid CAS Registry Number.
InChI:InChI=1/C54H69N11O10S2.C2H4O2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55;1-2(3)4/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74);1H3,(H,3,4)

127984-74-1 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Sigma

  • (SML0132)  Lanreotide acetate  ≥98% (HPLC)

  • 127984-74-1

  • SML0132-5MG

  • 1,130.22CNY

  • Detail
  • Sigma

  • (SML0132)  Lanreotide acetate  ≥98% (HPLC)

  • 127984-74-1

  • SML0132-25MG

  • 4,559.49CNY

  • Detail

127984-74-1Downstream Products

127984-74-1Relevant articles and documents

SUBSTANTIALLY PURE LANREOTIDE OR ITS SALT and PROCESS THEREOF

-

Page/Page column 24, (2020/09/08)

The present invention provides substantially pure Lanreotide or its salt and preparation thereof. In another aspect present invention provides a method of preparing Lanreotide dmg product which involves measuring D-Allo-Threonine Lanreotide impurity content in the Lanreotide or its salt. The present invention also provides a method of assaying purity of a sample of Lanreotide or its salt or a pharmaceutical dosage form comprising Lanreotide or its salt.

PROCESS FOR LANREOTIDE ACETATE PREPARATION

-

Page/Page column 21-22, (2018/01/15)

The invention relates to an improved method for 4+4 solution phase synthesis of Lanreotide acetate (1) comprising coupling of two suitably protected tetrapeptide fragments which on deprotection, oxidation, followed by treatment with acetic acid to provide Lanreotide acetate (1) having desired purity.

PROCESS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE SUSTAINED RELEASE OF SOMATOSTATIN ANALOGS

-

Paragraph 0111, (2016/12/16)

A process for the preparation of injectable pharmaceutical compositions for the sustained release of somatostatin analogues and compositions prepared according to the process. The process may comprise lyophilizing a mixture of lanreotide acetate and aceti

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 127984-74-1